Twitter Beğeni Hilesi

For advanced #endometrialcancer patients whose disease has recurred/progressed, the goal of treatment is palliative rather than curative. #ChallengeAccepted #GYNCSM

🎇 What a kickoff session at @asco #GU24 Maha and Neeraj. Two GIANTS in our field with two highly anticipated studies. Dena Battle David Braun Shuchi Gulati MD Sophia Kamran, MD Ruchika Talwar Karine Tawagi MD Yüksel Ürün Tian Zhang, MD, MHS Neeraj Agarwal, MD, FASCO ONCOassist® | The go-to oncology app 👇

The SGO Winter Meeting is underway, starting bright and early this morning with a great opening ceremony and meaningful educational sessions to a record-breaking audience of over 460 participants. Follow along in the #SGOMtg Flickr folder: ow.ly/hj3S50QusM3

HPN328 is a tri-specific T cell engager (x CD3+ albumin). X is ⬆️ in neuroendocrine prostate cancer. HPN328 is well tolerated (Cytokine release syndrome, SOB,fatigue) and active (SD in almost all NE CRPC ). Along with STEAP1 this is opening a new chapter of IO in CRPC #GU24

A diagnostic test that possesses that can predict therapy benefit and prognosticate long-term outcome, all through the use of AI and a small tissue sample! Exciting, cutting edge, and a definite advancement to patient care. #GU24 #prostatecancer

Wonderful talking to Neal Shore (CURC) on key #ProstateCancer updates at #GU24 including: ⭐️EMBARK, TALAPRO-2, PROpel, ARASENS and KEYNOTE-676 cohort A More to come on VJOncology.com 👀 ASCO OncoAlert #PCsm

Plus over 20 LBAs!! SGO FdtnForWomensCancer

Our 300th podcast discussing the controvacies in adjuvant therapy, the importance of OS, subsequent therapy, trial design and risk in bladder and renal cancer with David McDermott. Thanks for listening . Feel free to help us with feedback. anchor.fm/the-uromigos/e…

Raludotatug Deruxtecan Promising in Platinum-Resistant Advanced Ovarian Cancer medpagetoday.com/meetingcoverag…

We’ve got something cooking with our amigos, Uromigos … stay tuned!

#ASCO24 highlight video clips coming soon! Topline Bio

Great news for people with dMMR endometrial cancer Ramez Eskander Shannon Westin, MD, MPH, FASCO NRG Oncology The GOG Foundation Inc.

The exciting advancements of targeted therapies in gynecologic cancer brings hope to patients. 2024 has been an exciting year for the integration of targeted therapies in GYN oncology, bringing hope to patients and providers alike. #cervicalcancer #endometrialcancer

The emergence of more active bladder cancer systemic therapy has led to more patients with initial advanced disease who could be considered for consolidative cystectomy. Uromigos debate the timing and role of this maneuver…

Chromophobe RCC is a rare subtype of kidney cancer. Clinical outcomes from a large institution-based cohort are presented supporting IO-based combination therapy.  Brian Rini, MD shares his perspective…

Follow Topline Bio for more from Brian Rini, MD👍👍 Chemotherapy plus nivolumab has benefit in advanced bladder cancer, especially in the biologically-distinct subset of patients with lymph node only disease, just ask Uromigos

Thank you for being one of the Tres Uramigas!!

KIM-1 is a soluble protein with prognostic and predictive potential in resected RCC.  For more from the Uromigos on the data from IMmotion 010, click the link below… shorturl.at/uLNXN

Dr. Powles of the Uromigos sinks his teeth into ctDNA as an emerging, powerful tool to monitor prostate patients on therapy and how it may add to existing prognostic models…